Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
Descriptor ID |
D047428
|
MeSH Number(s) |
D27.505.519.389.755
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 2 | 2 |
2006 | 0 | 2 | 2 |
2007 | 0 | 2 | 2 |
2008 | 2 | 2 | 4 |
2009 | 2 | 4 | 6 |
2010 | 2 | 6 | 8 |
2011 | 6 | 2 | 8 |
2012 | 4 | 0 | 4 |
2013 | 3 | 7 | 10 |
2014 | 6 | 5 | 11 |
2015 | 6 | 3 | 9 |
2016 | 3 | 3 | 6 |
2017 | 7 | 0 | 7 |
2018 | 11 | 2 | 13 |
2019 | 6 | 2 | 8 |
2020 | 5 | 4 | 9 |
2021 | 3 | 3 | 6 |
2022 | 0 | 5 | 5 |
2023 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023 09 10; 41(26):4236-4246.
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
-
Progress and challenges in RET-targeted cancer therapy. Front Med. 2023 Apr; 17(2):207-219.
-
The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resist Updat. 2023 05; 68:100958.
-
Potential role for protein kinase D inhibitors in prostate cancer. J Mol Med (Berl). 2023 04; 101(4):341-349.
-
Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. Int J Hematol. 2022 Dec; 116(6):911-921.
-
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma. Br J Cancer. 2022 11; 127(11):1939-1953.
-
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. BMC Med. 2022 08 24; 20(1):257.
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 06 30; 386(26):2482-2494.